Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II multi-cohort study of AL2846 capsules in previously treated advanced solid tumors
CTR20223107Phase 2Completed
- Sponsor
- IDEXX Ningxin
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vilzemetkib in Nonhematologic neoplasms, sponsored by IDEXX Ningxin. Started Jan 2023; status: completed.
02
Drugs
vilzemetkib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20223107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223107.